Objectives:

1. Become familiar with the first line treatment options for EGFR mutation-positive lung cancer

2. Become familiar with at least 3 common mechanisms of acquired resistance to EGFR-directed therapy

3. Explain the role of immune therapy in the care of EGFR patients

Session date: 
Monday, May 14, 2018 - 12:00pm to 1:00pm
Speaker Name: 
Lecia V. Sequist, MD, MPH
Location: 
UCMC/Knapp Center for Biomedical Discovery
900 East 57th Street
Conference Room 1103
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.